# The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

> **NCT00894530** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 314 (actual)

## Conditions studied

- Blepharitis

## Interventions

- **DRUG:** Azithromycin ophthalmic solution, 1%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00894530
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2013-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894530, "The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00894530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*